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Abstract
Background: Menopause can lead to alterations in women’s health, with changes in the oxidative status of postmenopausal 
women in whom information regarding the influence of hormone therapy (HT) on antioxidant enzyme activities is limited.
Objective: To evaluate the influence of HT on catalase activity; concentrations of lipids and lipoprotein, cholesteryl 
ester transfer protein, thiobarbituric acid-reactive substances, nitrates, high-sensitivity C-reactive protein and carotid 
thickness in postmenopausal women.
Methods: Ninety-four consecutive women were allocated to one of four groups, without HT and with HT. The latter group 
was subdivided into women using estrogen and those using estrogen plus progestogen therapy. Plasma biochemical 
parameters and common carotid intima-media thickness measurements were performed.
Results: HT antagonized the decrease in catalase activity after menopause, but had no effect on the levels of cholesteryl 
ester transfer protein, thiobarbituric acid-reactive substances, lipid peroxide, nitrate, high-sensitivity C-reactive protein, 
or on the common carotid intima-media thickness. Multivariate analysis showed that estrogen-based HT attenuated the 
relationship between cardiovascular risk factors and the intima-media thickness of the common carotid.
Conclusion: This study indicates that HT in postmenopausal women produces beneficial antioxidant and 
anti-atherosclerotic effects by ameliorating the plasma lipid and lipoprotein profiles, increasing plasma catalase 
activity and attenuating the association between cardiovascular risk factors and early atherosclerosis. (Arq Bras Cardiol 
2012;99(5):1008-1014)
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Introduction
The role of oxidative stress in atherosclerosis has received 
considerable attention, with atherogenesis being triggered 
by focal inflammation and cellular proliferation1. Antioxidant 
enzymes such as catalase, superoxide dismutase e glutathione 
peroxidase, protect aerobic cells against oxidative injury 
caused by reactive oxygen species (ROS) generated during 
normal cellular metabolism1. Oxidative stress resulting from 
the overproduction of ROS or a deficiency in the enzymatic 
and non-enzymatic antioxidant systems can lead to a 
number of pathological conditions and contribute to aging1. 
Menopause can lead to alterations in women´s health, 
with excessive ROS formation and changes in the oxidative 
status of postmenopausal women2-5. However, few studies 
have examined the influence of hormone therapy (HT) on 
antioxidant enzyme activity in postmenopausal women and 
have focused on short-term use of HT.
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The cardiovascular effects of HT have been the subject 
of much debate since the initial findings from the Women’s 
Health Initiative (WHI study) were reported. However, 
re-analyses of WHI results have suggested that the association 
between HT use and cardiovascular risk is influenced by 
several factors, among these, age and time since menopause. 
Observational and randomized studies have suggested that 
initiation of hormone replacement therapy (HT) in early 
postmenopause could be beneficial from a cardiovascular 
point of view. Conversely, aging, time since menopause 
and presence of cardiovascular risk factors or cardiovascular 
disease may decrease its efficacy and increase the risk of 
cardiovascular events6. 
In the last ten years, HT for the treatment of menopausal 
symptoms is a real option that led to recently launched studies 
on the antioxidant effects of estrogen. In addition to its effects 
on the post-menopausal symptoms estrogen therapy has been 
used to treat osteoporosis7 and many postmenopausal women 
have been using it.
The intima-media thickness of the common carotid artery 
(carotid IMT), an appropriate intermediate endpoint for 
investigating clinically relevant effects on atherogenesis, can 
be used to assess the early stages of atherosclerosis, since 
this parameter correlates with risk factors, including age, 
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Samples
Blood samples were collected from patients by 
venipuncture into ethylenediamine tetraacetic acid (EDTA) 
after a 12 h fast. Plasma was obtained by centrifugation at 
1000 g for 10 min at 4°C.
General Analytical Methods
Total cholesterol and triglycerides were determined by 
an enzymatic-colorimetric method (Hitachi 917, Roche, 
Mannheim, Germany). Plasma LDL and HDL cholesterol were 
analyzed in sample supernatants by a homogeneous direct 
enzymatic-colorimetric method after precipitation of apoB 
100-containing lipoproteins. Apolipoproteins (AI and B 100) 
were determined by nephelometry.  
Nitrate, the stable metabolite of nitric oxide, was measured 
with Greiss reagent in a commercial nitrate/nitrite assay kit 
(Cayman Chemical Co, Ann Arbor, Michigan, USA)15. Catalase 
activity, thiobarbituric acid-reactive substances (TBARS) and 
lipoperoxidases (LPO) concentrations were assayed in plasma 
by ELISA and colorimetric methods (Cayman Chemical 
Co, Ann Arbor, Michigan, USA)16,17. The concentration of 
high-sensitive CRP was determined with a Behring 
latex-enhanced CRP assay and a Behring nephelometer 
analyzer system (Dade Behring, Tokyo, Japan). 
The intima-media thickness of the common carotid artery 
was measured with an HDI 1500 ultrasound system (ATL 
Ultrasound, Botheli, WA, USA) fitted with a 7-12 MHz color 
Doppler probe. The carotid IMT was calculated as the mean of 
five measurements in the far wall of the left and right common 
carotid arteries, according to a standardized method9. 
Individual results (expressed in mm) were the average of the 
left and right carotid IMT.
Statistical Analysis
Results are expressed as means ± SD. Statistical analyses 
were carried out using ANCOVA with rank transformation, 
adjusted for age and BMI, or the Mann-Whitney test. 
Spearman’s test was used to examine the correlation between 
variables in the groups. Multiple linear regression analysis with 
stepwise criteria for the selection of variables was used to assess 
the influence of lipoproteins, apolipoproteins, cholesteryl ester 
transfer protein (CETP), catalase, nitrate, TBARS, LPO and 
hs-CRP serum concentrations on carotid IMT. The results were 
expressed as coefficients of determination (R2) that represented 
the percentage of variation in the dependent variable that was 
explained by the independent variables. A value of p < 0.05 
(two-tailed test) indicated significance. All data and statistical 
analyses were performed with the SAS statistical package (SAS 
Institute Inc, Cary, NC, USA).
Results 
Table 1 summarizes the clinical and biochemical 
characteristics of the subjects. There was no difference in 
the mean age or blood pressure of the WTHT and WHT 
groups, but a significant difference was observed in the BMI 
(29 kg/m2 and 26 kg/m2, respectively; p = 0.021) and waist 
circumference (89 cm and 83 cm, respectively; p = 0.007) 
dyslipidemias and oxidative stress8. Information regarding the 
influence of HT on carotid atherosclerosis is limited; whereas 
experimental and epidemiological studies have reported 
that HT has a beneficial effect on the progression of carotid 
IMT in postmenopausal women9, others have observed no 
significant effect10. In contrast, it has been reported that while 
HT may prevent the development of atherosclerotic plaques 
in postmenopausal women9, there is no difference in the 
carotid IMT between women who had and had not used HT11. 
Lipid and lipoprotein metabolism is markedly altered after 
menopause12-14 with a natural reduction in estrogen levels. 
In this study, we investigated the serum catalase activity; 
serum concentrations of lipids and lipoprotein, cholesteryl 
ester transfer protein, thiobarbituric acid-reactive 
substances (TBARS), nitrate and hs-CRP plasma levels in 
postmenopausal women with or without HT, in order to 
determine whether postmenopausal HT influences the 
levels of oxidative stress (a proinflammatory marker). The 
thickness of the common carotid intima-media was used 
as an early marker of atherosclerosis. 
Methods
Subjects
Ninety four postmenopausal women (POMW) mean age: 
59 years, were assigned to one of two groups: those without 
HT (WTHT, n = 63) and those with HT (WHT, n = 31); 
the women in the latter group were further subdivided 
into those using estrogen therapy (ET, conjugated equine 
estrogen, 0.625 mg/d; n = 20) and those using estrogen plus 
progestogen therapy (EPT, methoxyprogesterone acetate, 
2.5-5 mg/d; n = 11). They were sequentially recruited at the 
University Clinic during a one-year period, according to the 
criteria presented below.
The POMW were clinically evaluated at the Dyslipidemia 
and Menopause Outpatient Clinics of the School of Medical 
Sciences of UNICAMP. The presence of menopause was 
defined among women ≥ 40 years old with at least one year 
of natural menopause or surgical bilateral oophorectomy, 
in accordance with the criteria of the North American 
Menopause Society14. The exclusion criteria for participation 
in the study were: severe dyslipidemia (HDL cholesterol 
≤ 40 mg/L, LDL cholesterol ≥ 190 mg/L and triglycerides 
≥ 400 mg/L), smoking, alcoholism, severe systemic disease 
including nephropathy, endocrinopathy and pneumopathy.
The criterium for body mass index (BMI) ≤ 27 kg/m2 13 was 
reached in half of the women studied.
Vasomotor symptoms (hot flashes and night sweats) were 
the main indication for the use of systemic HT14. All POMW 
had been on HT with continuous oral estrogen (0.625 mg/d) or 
continuous estrogen (0.625 mg/d) and methoxyprogesterone 
acetate (2.5 or 5 mg/d) for at least one year (mean of five 
years). All of the subjects gave written informed consent to 
participate in the study. 
This investigation was approved by the institutional 
Research Ethics Committee (protocol no. 314/2004).
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of the two groups. The mean carotid IMT ranged from 
0.83 mm to 0.91 mm, with no difference between the two 
postmenopausal groups.
The mean serum total cholesterol concentration in 
POMW exceeded the maximum recommended value of 
200 mg/dL (Table 2). Higher LDLchol and NHDLchol (non 
HDL cholesterol) levels were observed in WTHT versus 
WHT postmenopausal women (p = 0.013 and 0.048 
for LDL and NHDLchol, respectively) (Table 2), whereas 
lipoprotein (a) remained unchanged. Increased HDLchol 
was observed in postmenopausal women with estrogen 
therapy, compared to those with estrogen plus progestogen 
therapy (p = 0.041). Insulin levels were identical in all 
groups (not shown). The Castelli II index (LDLchol/HDLchol) 
decreased in HT with estrogen. CETP activity was similar 
in all groups.
Table 3 shows that, with the exception of catalase, which 
increased by approximately 42% in the WHT and EPT 
groups, there were no significant differences in the levels of 
the other biomarkers of oxidative stress and inflammation 
between the groups.
Strong correlations were observed between three 
risk factors for atherosclerosis (age, hs-CRP and waist 
circumference) and carotid IMT in the WTHT group, but 
Table 1 - Anthropometric and radiological parameters of postmenopausal women with (wht) and without (wtht) hormone replacement therapy (ht)
Group/ 
Parameter Age (years) BMI (kg/m
2) SBP(mmHg)
DBP
(mmHg) WC (cm) IMT(mm)
POMW 58±8 (94) 28±5 (94) 120±1.0(94) 80±0.9 (94) 87 ± 13 (92) 0.88±0.2 (84)
WTHT 59±7(63) 29.21±5(63) 120±1.1(63) 80.1±0.1(63) 893, 4±14(63) 0.89±0.19(55)
WHT 56±8(31) 26.41, 2±4(31) 120±0.9(31) 79±0.8(31) 833±10(31) 0.85±0.14(29)
ET 56±9(20) 25.72±4(20) 120±0.5(20) 79±0.7(20) 804±9(20) 0.83±0.14(20)
EPT 57±7(11) 28.0±4(11) 120±1.4(11) 80±0.9(11) 88±9(11) 0.91±0.14(9)
The values are the mean±SD of the number of subjects indicated in parentheses, POMW: postmenopausal women; WTHT: without HT; WHT: with HT; ET: estrogen 
therapy; EPT: estrogen plus progestogen therapy; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; IMT: carotid intima-media 
thickness;  WC: waist circumference; 1p(29.2x26.4)=0.021; 2p(26.4x25.7); 3p(89x83) =0.007; 4p=0.0184 (Mann-Whitney test between 2 groups and Kruskal-Wallis 
test between 3 groups).
Table 2 - Lipid, lipoproteins and cholesteryl ester transfer protein levels in postmenopausal women with (wht) and without (wtht) hormone 
replacement therapy (ht)
Parameter/Group POMW WTHT WHT ET EPT
Cholesterol
(mg/dL) 224±39 (94) 229±40 (63) 215±36 (31) 215±37 (20) 213±36 (11)
HDLchol
(mg/dL) 61±14 (94) 60±12 (63) 65±17 (31) 69±17
3 (20) 57±143(11)
LDLchol
(mg/dL) 133±36 (94) 140±34
1,4(63) 118±371(31) 115±404(20) 126±29 (11)
NHDLchol
(mg/dL) 164±40 (94) 170±40
2(63) 151±402(31) 148±40 (20) 157±41 (11)
Triglycerides
(mg/dL) 153±89 (94) 147±66 (63) 165±224 (31) 158±88 (20) 178±176 (11)
LDLchol/HDLchol 2.4±0.7 (94) 2.41±0.75,6(63) 1.93±0.85(31) 1.76±0.86(20) 2.27±0.8 (11)
APO AI
(mg/dL) 172±26 (94) 167±24 (63) 181±30 (31) 188±33 (20) 167±17 (11)
APO B100
(mg/dL) 120±27(94) 123±28 (63) 115±25 (31) 113±23 (20) 116±29 (11)
Lp(a)
(mg/dL) 29±30 (94) 28±29 (63) 32±30 (31) 24±27(20) 44±35 (11)
CETP
(% CE transfer) 32 ± 12 (93) 32 ± 11 (61) 32 ± 13 (31) 31 ± 14 (20) 34 ± 11 (11)
The values are the mean±SD of the number of subjects indicated in parentheses. ), POMW: postmenopausal women; WTHT: without HT; WHT: with HT; ET: estrogen 
therapy; EPT: estrogen plus progestogen therapy; APO A1: apolipoprotein AI; APO B: apolipoprotein B; CETP: cholesterol ester transfer protein; HDLchol: high-density 
cholesterol lipoprotein; LDLchol: low-density cholesterol lipoprotein; LDLchol/HDLchol: Castelli II; Lp(a): lipoprotein (a); and NHDLchol: no high-density cholesterol 
lipoprotein 1p= 0.013; 2p= 0.048; 3p=0.041; 4p=0.034; 5p=0.017 and 6p=0.013. (Mann-Whitney test between 2 groups and Kruskal-Wallis test between 3 groups.
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Table 3 - Oxidative and inflammatory biomarkers in postmenopausal women with (wht) and without (wtht) hormone replacement therapy (ht)
Parameter/Group Catalase (nmol/min/ml)
Nitrate
(µM)
TBARS 
(nmol/tmp/gprot)
Lipid peroxides
(umoles/L)
hs-CRP
(mg/L)
WTHT 22±241,2(62) 8.6±6(62) 2.8±1.1(55) 4.3±1.0(29) 0.5±0.8(61)
WHT 38±301(30) 9±7(31) 2.4±0.9(26) 5.3±4.8(24) 0.4±0.4(29)
ET 39±31(20) 8.2±5(20) 2.4±0.8(17) 5.8±5.7(17) 0.5±0.4(19)
EPT 37±302(10) 10±11(11) 2.4±1.1(9) 4.2±0.9(7) 0.4±0.4(10)
The values are the mean±SD of the number of subjects indicated in parentheses;  WTHT: without HT; WHT: with HT; ET: estrogen therapy; EPT: estrogen plus 
progestogen therapy; hs-CRP: high-sensitivity C-reactive protein; nitrate: nitrate/nitrites; and TBARS: thiobarbituric acid-reactive substances. 1p (22x38)= 0.015; and 
2p (22x37)= 0.029. (Mann-Whitney Test between 2 groups and Kruskal-Wallis test between 3 groups.
Table 4 - Correlation coefficients for carotid INTIMA-MEDIA THICKNESS versus metabolic or anthropometric variables in postmenopausal 
women without hormone replacement therapy (wtht) and those on estrogen plus progestogen therapy (ept)
WTHT (n=55) Age WC hs-CRP
Right IMT (mm) 0.386 (0.004) 0.316 (0.018) 0.430 (0.043)
Left IMT (mm) 0.400 (0.003) 0.0186 (0.316) 0.306 (0.026)
Mean IMT (mm) 0.414 (0.002) 0.296 (0.028) 0.308 (0.025)
EPT (n=9) SBP LDLchol -
Right IMT (mm) - 0.826 (0.011) -
Left IMT (mm) 0.734 (0.025) 0.766 (0.027) -
Mean IMT (mm) 0.686 (0.041) 0.826 (0.002) -
The corresponding p values are indicated in parentheses. EPT: estrogen plus progestogen therapy; hs-CRP: high-sensitivity C-reactive protein; IMT: carotid intima-
media thickness; LDLchol: low-density lipoprotein cholesterol; SBP: systolic blood pressure; and WC: waist circumference.
these were abolished by HT in the EPT group (Table 4). 
However, the EPT group still retained important correlations 
between carotid IMT and LDLchol and systolic blood 
pressure, two well-known markers for atherosclerosis. 
Regression analysis showed that, in WTHT women, 
carotid IMT was positively correlated with age and nitrate 
and hs-CRP levels, but negatively correlated with Lp (a) 
levels (Table 5). In WHT women, carotid IMT was positively 
correlated with age and waist circumference, whereas in 
ET women, the carotid IMT was negatively correlated with 
age and lipoprotein levels. The latter finding suggests a 
protective action of estrogen. 
Discussion
Oxidative stress has a central role in lipid peroxidation 
and inflammation associated with atherosclerosis, with 
inflammation being particularly important in mediating 
all stages of this disease18. However, the usefulness of 
antioxidant measures to treat patients with atherosclerosis 
has not been conclusively proven.
HT has cardioprotective actions that may be associated 
with changes in circulating lipoprotein levels19. As shown 
here, women with HT had significantly lower plasma levels 
of LDLchol (p = 0.013) and NHDLchol (p = 0.048), and 
a lower LDLchol/HDLchol ratio (p = 0.001), although ET 
women had higher HDLchol than EPT women (p = 0.041). 
Changes in the plasma lipoprotein profile, mediated 
by the transfer of neutral lipids, such as cholesteryl ester 
and triglyceride, are the best known function of CETP20. 
Experimental and epidemiological studies indicate that 
CETP may play an important role in the development of 
atherosclerosis20-21, although the precise effects of CETP on 
atherogenesis are still controversial. In humans, an increased 
incidence of coronary heart disease has been associated 
with a deficiency22 or increase23 in CETP. Although CETP is a 
potential therapeutic target24, the usefulness of interventions 
involving this protein will depend on clarification of its role in 
atherogenesis. As shown here, CETP was unaffected by HT, in 
agreement with a previous study in postmenopausal women5. 
Free radical-induced lipid peroxidation has been 
proposed as an etiological factor in ageing after menopause 
and in various age-related diseases, including atherosclerosis. 
In the present study, there were no differences in the serum 
LPO and TBARS levels (indicators of lipid peroxidation 
and free-radical production, respectively) between the 
WTHT and WHT groups. These data differ from previous 
findings25 and from the significantly higher TBARS levels 
in postmenopausal women under HT26. The discrepancy 
between our study and the already-mentioned report may 
be related to differences in the mean ages of the groups 
that were studied, namely, 59 and 56 years in our WTHT 
and WHT women, respectively, compared to 47 and 52 
years for WTHT and WHT women, respectively, in Kesim 
et al’s study26.
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The nitric oxide synthase expressed within the vascular 
wall is a target of estrogen action and produces a number 
of beneficial effects on vascular biology. As a woman 
ages, NOS becomes increasingly higher and starts 
to produce superoxide, a dangerous reactive oxygen species. 
It is the biochemical environment around NOS that will 
determine whether estrogen produces a beneficial nitric 
oxide or deleterious (superoxide) product, and can account 
for this dual and opposite nature of estrogen pharmacology27. 
The lack of difference in the serum nitrate/nitrite levels of 
WTHT and WHT women agreed with data reported by kesim 
et al.26, but differed from those of Bednarek-Tupikowska et 
al.25 and Salhotra et al.28, who reported significantly higher 
nitrite levels in postmenopausal women under HT. 
Age-dependent deficiency of estradiol and antioxidant 
glutathione in blood of postmenopausal women causes 
compensatory activity of catalase, which is not always enough 
to counteract oxidative stress.
Several reports have suggested a connection between 
estrogen exposure and catalase activity. Catalase is a 
primary antioxidant defense component that catalyzes 
the decomposition of hydrogen peroxide to water29-30. 
HT antagonized the decrease in catalase activity normally 
associated with menopause (catalase activity: 22% in WTHT 
women, compared to 37% in ET women; p = 0.029).
These findings differed from those of other studies 
that reported no difference in catalase activities of WTHT 
and WHT women27 or higher levels in postmenopausal 
women31-36. 
Treatment of normal human breast epithelial cells in 
culture with estradiol was shown to decrease cellular catalase 
activity37. Further, treatment of breast cancer cell lines with 
estradiol resulted in decreased catalase activity in the estrogen 
receptor (ER)–positive but not the ER-negative cell lines37. 
Table 5 - Multiple linear regression coefficients for carotid intima-media thickness in postmenopausal women with (wht) and without (wtht) 
hormone replacement therapy (ht)
Group Independent variables Parameters p Cumulative R2
WTHT (n=20) 0.8788
Age 0.0022 <0.001
Lp(a) -0.0014 0.035
Nitrates 0.0095 0.003
hs-CRP 0.2298 0.000
WHT (n=13) 0.3810
Age 0.0043 0.416
WC 0.0118 0.048
ET (n=9) 0.8748
Age -0.1120 0.026
LPO -0.1724 0.041
hs-CRP: high sensitivity C-reactive protein, Lp(a): lipoprotein (a), LPO: lipoperoxides and WC: waist circumference, WTHT: without HT, WHT: with HT, ET: 
estrogen therapy.
The discrepancy between our study and other reports 
may be related to the small number of patients in each group 
studied. The magnitude of the decrease in catalase activity 
may depend on other factors such as race, diet and the 
individual expressing forms of the catalase polymorphism, 
although our study did not permit detailed subgroup analysis 
by diet status, race or catalase polymorphism38. Escalante 
Gómez and Quesada Mora39 studied the effect on DNA 
oxidation as a possible explanation for the aging process itself 
and the effects that HT has on them, and found no statistical 
difference for protein oxidation and catalase activity among 
the groups. They concluded that HT decreases oxidative 
damage to both DNA and lipids in postmenopausal women, 
in corroboration to our findings39. 
In addition, comprehensive information regarding 
potential confounding factors were available, and the HT-use 
information was collected using a detailed questionnaire, 
which, although subject to recall bias, referred to behavior 
in the past.
HT did not alter the carotid IMT in WHT women, or 
in the subgroups ET and EPT. However, mean carotid IMT 
was positively correlated with age, waist circumference and 
hs-CRP levels; this correlation disappeared with HT. In 
addition, multiple regression analysis showed negative 
relationships for age and LPO after estrogen HT, indicating 
a protective effect of hormonal treatment. This small study 
indicates the need for more extensive studies to investigate 
the differential roles of whether postmenopausal HT 
influences the levels of oxidative stress.
Conclusions
This study indicates that HT in postmenopausal women 
produces beneficial antioxidant and anti-atherosclerotic effects by 
ameliorating the plasma lipid and lipoprotein profiles, increasing 
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plasma catalase activity and attenuating the association between 
cardiovascular risk factors and early atherosclerosis.
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